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BACKGROUND: Oral cancer is a common and lethal malignancy. Direct contact between saliva and the oral cancer lesion makes
measurement of tumour markers in saliva an attractive alternative to serum testing.
METHODS: We tested 19 tongue cancer patients, measuring the levels of 8 salivary markers related to oxidative stress, DNA repair,
carcinogenesis, metastasis and cellular proliferation and death.
RESULTS: Five markers increased in cancer patients by 39–246%: carbonyls, lactate dehydrogenase, metalloproteinase-9 (MMP-9), Ki67
and Cyclin D1 (CycD1) (Pp0.01). Three markers decreased by 16–29%: 8-oxoguanine DNA glycosylase, phosphorylated-Src and
mammary serine protease inhibitor (Maspin) (Pp0.01). Increase in salivary carbonyls was profound (by 246%, P¼0.012); alterations
in CycD1 (87% increase, P¼0.000006) and Maspin (29% decrease, P¼0.007) were especially significant. Sensitivity values of these
eight analysed markers ranged from 58% to 100%; specificity values ranged from 42% to 100%. Both values were especially high for
the CycD1 and Maspin markers, 100% for each value of each marker. These were also high for carbonyls, 90% and 80%, respectively,
and for MMP-9, 100% and 79%, respectively.
CONCLUSIONS: The significance of each salivary alteration is discussed. As all alterations correlated with each other, they may belong to
a single carcinogenetic network. Cancer-related changes in salivary tumour markers may be used as a diagnostic tool for diagnosis,
prognosis and post-operative monitoring.
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Salivary testing, a non-invasive alternative to serum testing, can be
an effective modality for diagnosis and prognosis predicting of oral
cancer as well as for monitoring the patient’s post-therapy status
(Nagler et al, 2006). Oral cancer (oral squamous cell carcinoma,
OSCC) is the sixth most common human malignancy, with a 5-year
mortality rate of approximately 50% (Myers et al, 2000; Kantola
et al, 2000), which has not changed significantly in more than 50
years, and a high rate of morbidity (Yuen et al, 1998; Ribeiro et al,
2000; Sparano et al, 2004). The therapeutic modality currently
offered to OSCC patients is based on traditional stage-predicting
indices (based mostly on the TNM criteria) and on histological
grading. Unfortunately, these predictors are subjective and
relatively unreliable, as two tumours with identical staging and
grading often behave very differently; though one responds to
therapy, the other may be lethal. Thus, there has been an ever-
growing effort dedicated to the basic research of oral cancer,
focusing on the identification of biological indicators for the
diagnosis of its biological nature and aggressiveness. However,
very few studies have examined tumour markers in the saliva of
OSCC patients, though such an examination might be of great
benefit because of the direct contact between the oral cancer lesion
and saliva. The purpose of this study was to concurrently examine
in the saliva of the OSCC (tongue) patients the following eight
biomarkers that have been suggested earlier to be related to OSCC
(mostly by tissue analysis): carbonyls, 8-oxoguanine DNA
glycosylase (OGG1), mammary serine protease inhibitor (Maspin),
Ki67, phosphorylated-Src (phospho-Src), Cyclin D1 (CycD1),
metalloproteinase-9 (MMP-9) and lactate dehydrogenase (LDH).
MMP-9 and LDH have been measured quativavely in saliva of
OSCC cancer patients whereas salivary carbonyls were studied by
a western gel only. Studies of the other five markers have never
been published in the professional literature (Bahar et al, 2007;
Shpitzer et al, 2007). Furthermore, all eight markers have never
been studied simultanously, nor have they been related to each
other or evaluated for their diagnostic sensitivity and specificity
values, or for their mutual pathogenetic role in OSCC.
MATERIALS AND METHODS
Patients and study design
The data analysed in this study relate to 19 consecutive patients
who were diagnosed with tongue cancer. This study group
included 12 females and 7 males, mean age 66±4 (range 27–86),
who were compared with a control group with a similar age and
gender distribution. The data obtained included staging (according
to the TNM criteria), histological grading, depth of the tumour,
maximal tumour diameter, localisation at the base vs mobile part
of the tongue and the patients, smoking habit, age and gender. Received 11 May 2009; revised 20 July 2009; accepted 1 August 2009
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Src, CycD1, Ki67, MMP-9 and LDH was performed. These were
measured in saliva, which was collected as described earlier
(Nagler et al, 2002), shortly before the administration of the
definitive curative treatment. This included surgical removal of
the primary tongue tumour, neck dissection and, in most cases,
post-operative adjuvant radiotherapy.
Immunoreactivity assay for salivary markers
Saliva samples were centrifuged (800g, 10min, 41C), and the
pellets were suspended in 150ml of lysis buffer (45mM HEPES,
0.4 M KCl, 1mM EDTA, 10% glycerol, pH 7.8). After 30min
incubation at room temperature the samples were centrifuged
(11000g, 10min, 41C). Protein concentrations in the supernatants
were determined. A volume containing 50ng of protein was
transferred to a 1.5ml vial and all samples were brought to the
same volume of 500ml with the addition of PBS. The solutions were
mixed well and 100ml of each sample was added to ELISA-plate
wells (nunc-immunoplate; Thermo Fisher Scientific, Waltham,
MA, USA). The plate was covered and stored overnight at 41C. The
next day, each well was washed three times with 100ml PBS–Tween
solution (PBS-T, PBS containing 0.05% Tween 20) and a volume
of 100ml of 1% BSA PBS-T blocking solution (PBS containing
0.05% Tween 20 and 1% BSA) was added to each well. After 1h
incubation at room temperature, 100ml of primary antibody was
added to each well. After 2h incubation at room temperature, the
plate was washed as described above and a volume of 100mlo f
secondary antibody was added to each well. After 2h incubation at
room temperature the plate was washed as described above. To
achieve colour development, we added 100ml of 3,30,5,50-tetra-
methylbenzidine solution (Southern Biotech, Birmingham, AL,
USA) to each well. After 1–2min, we added 100ml of stopping
reagent to each well (10% sulphuric acid). Absorbencies of the
samples, representing the levels of the specific proteins examined,
were measured at the wavelength 450nm directly after the addition
of the stopping reagent, using a Zenith 200 ELISA reader (Anthos,
Eugendorf, Austria). For MMP-9, we used a polyclonal rabbit anti-
human antibody (1:1000; Sigma-Aldrich, Saint Louis, MO, USA).
For OGG1, we used a polyclonal rabbit anti-human antibody
(1:10000; Alpha Diagnostic International, San Antonio, TX, USA).
For phospho-Src, we used a polyclonal rabbit anti-human antibody
(1:1000; Sigma-Aldrich). For Ki67, we used a monoclonal
rabbit anti-human antibody (1:1000; Acris Antibodies, Herford,
Germany). For Maspin, we used a polyclonal rabbit anti-human
antibody (1:1000; Sigma-Aldrich). For CycD1, we used a
polyclonal rabbit anti-human antibody (1:500; Sigma-Aldrich).
For all assays we used a peroxidase-conjugated goat anti-rabbit
secondary antibody (1:5000; Jackson Immunoresearch, West
Grove, PA, USA).
Detection of protein oxidation (protein carbonyl assay)
An enzyme-linked immunosorbent assay (ELISA) colorimetric test
kit (BioCell Corporation Ltd., Papatoetoe, New Zealand) was used
to quantitatively measure the products of protein oxidation
(carbonyls) in saliva samples. Samples were centrifuged (800g,
10min, 41C), and the pellets were suspended in 150ml of lysis
buffer (45mM HEPES, 0.4M KCl, 1mM EDTA, 10% glycerol, pH
7.8). After 30min incubation at room temperature the samples
were centrifuged (11000g, 10min, 41C) and the supernatants
were stored at  201C. On the day of the carbonyl analysis, the
supernatants were thawed and protein concentrations were
determined. A volume of 20mg was transferred to a 1.5ml vial
and all samples were brought to the same volume of 100ml with the
addition of water of high-pressure liquid chromatography grade.
We added 0.8 volumes of ice cold 28% trichloroacetic acid, mixed
well, and after 10min of incubation on ice the tubes were
centrifuged (10000g, 3min, 41C). Supernatants were carefully
aspirated without disturbing the pellet; 5ml of EIA buffer (1 M
phosphate solution containing 1% BSA, 4 M NaCl, 10mM EDTA
and 0.1% sodium azide) and 15ml diluted 2,4-dinitrophenol (DNP)
solution were added to pellets according to the manufacturer’s
instructions. After 45min incubation at room temperature, 5mlo f
each sample was taken to a parallel set of 1.5ml vials containing
1ml EIA buffer. The solutions were mixed well and 200ml of each
sample was added to ELISA-plate wells. The plate was covered and
stored overnight at 41C. The next day, the plate was washed three
times with EIA buffer (250ml per well) and 250ml of diluted
blocking solution (provided by the manufacturer) was added to
each well. After 30min incubation at room temperature, the wells
were washed as described above and 200ml of diluted anti-DNP-
biotin-antibody was added to each well. The plate was incubated
for 1h at 371C. After incubation, the plate was washed and 200ml
of diluted streptavidin–HRP was added to each well. After 1h
incubation at room temperature the plate was washed as described
above. To achieve colour development, we added 200mlo f
chromatin reagent (provided by the manufacturer) to each well.
After 5min, we added 100ml of stopping reagent to each well.
Absorbencies of the samples were measured at the wavelength
450nm directly after the addition of the stopping reagent, using a
Zenith 200 ELISA reader (Anthos). To quantify the absorbance
values, we performed the same procedure for standard and control
samples provided by the manufacturer, and created a standard curve.
LDH activity
For the measurement of LDH activity, saliva samples were diluted
by a factor of 10 using double-distilled water. The activity of LDH
was determined by kinetic spectrophotometry using a commercial
kit (REF DF53A, Siemens Healthcare Diagnostics, Deerfield,
IL, USA) and a Dimension RXL analyser (Siemens Healthcare
Diagnostics).
Statistical analysis
Data concerning the levels of various markers were evaluated in
saliva, and the mean, standard deviation (s.d.) and mean standard
error (s.e.) values were analysed and compared with the two-
sample t-test for differences in means. The criterion for statistical
significance was Po0.05. The correlations between the marker
levels in saliva were analysed using the Pearson correlation
analysis. A correlation matrix of estimators was used to analyse
the correlation coefficients between the salivary parameters. For
classification analysis, cutoff values were calculated as mean plus/
minus 1 s.d. value of healthy controls. Sensitivity and specificity
values were calculated as the fraction of observations, which were
correctly classified.
RESULTS
Clinical data staging, pathological grading, dimensions,
site and extension of the tumours
The distribution of the 19 patients according to tumour size (T)
showed that 7 had T1 and 8 patients had T2 tumours whereas only
2 patients had T3 and 2 patients had T4 tumours. That is, nearly
80% of the patients had early (small to moderate) tumours. In 13
out of 19 (68%) of the patients there were no neck metastases (N0)
whereas 4 patients were diagnosed with N1 and 2 with N2. None
had distant metastasis (all patients were M0). Accordingly, 68%
of the patients were diagnosed with early stage tumours (1þ2)
whereas only 32% were diagnosed with advanced stages (3þ4).
Similarly, most of the patients (84%) were diagnosed with well
differentiated and moderately differentiated tumours and only
three patients were diagnosed with poorly differentiated lesions.
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the lingual region and expanded locally towards neighbouring
regions, towards the floor of the mouth.
The mean tumour diameter at diagnosis was 3.4±0.9cm (range
0.5–8.0cm) and the mean depth was 3.4±0.9mm (range
1–25mm). Only 12.5% of the patients smoked (2 of the 16 for
whom this information was available). The rate of smokers in the
control group was not significantly different. Only 2 out of 19
patients had a previous pre-malignant lesion (Lichen planus), only
1 out of 17 patients (for whom the data were available) had other
previous malignancy and none had been treated earlier with
radiotherapy. None of the controls was treated with radiotherapy
or had head and neck cancer earlier.
Salivary tumour markers
Salivary tumour marker analysis showed highly significantly
changes in the levels of all eight markers analysed (Table 1;
Figure 1). Five of these were increased in the cancer patients by
39–246%: carbonyls, Ki67, CycD1, MMP-9 and LDH (Pp0.01).
The other three markers were decreased in the cancer patients by
16–29%: OGG1, Maspin and phospho-Src (Pp0.01).
The salivary mean (±s.e.) concentrations (OD values) in
controls of MMP-9, carbonyls, Ki67, CycD1, OGG1, phospho-Src
and Maspin were 0.04±0, 0.37±0.23, 0.15±0.05, 0.70±0.03,
0.50±0.02, 0.67±0.03 and 0.44±0.02, respectively. The increase
in salivary carbonyls was profound (by 246%, P¼0.012) and
especially significant were the alterations in CycD1 (an increase by
87%, P¼0.000006) and in Maspin (a decrease by 29%, P¼0.007)
(Table 1). The salivary mean (±s.e.) LDH activity value (the only
value presented absolutely) in controls was 390±73m/l (Figure 1).
The sensitivity values of the eight analysed markers were in the
range of 58–100% whereas the specificity values were in the range
of 42–100% (Table 1).
The sensitivity and specificity values were especially high
for the CycD1 and Maspin markers, 100% for each value of
each marker. These were also quite high for the carbonyls,
90% and 80%, respectively, and for the MMP-9, 100% and 79%,
respectively.
Multiple significant (ro 0.4 or 40.4) correlations were shown
among all eight markers, each with some of the others. The most
significant correlations were shown between: Maspin and CycD1
(0.89), carbonyls and CycD1 (0.79), carbonyls and Maspin (0.75)
and carbonyls and Ki67 (0.72). In addition, quite high were the
significant correlations between CycD1 and MMP-9 (0.67) and
between Maspin and OGG1 (0.62) (Table 2).
DISCUSSION
A most important result found in this study is that all eight salivary
parameters analysed in the cancer patients were altered in a highly
significant manner, and were characterised by relatively high
sensitivity and specificity values. Moreover, all markers ‘talked
with each other’, that is these alterations significantly correlated
among themselves, indicating that they all belong to a single
carcinogenetic network that, when fully understood, may be used
for the development of anti-cancer drugs related to OSCC. We thus
believe that the demonstrated results are of a significant merit with
respect to both the clinical and the pathogenesis-related aspects of
oral cancer. These significant demonstrated alterations in salivary
markers of the cancer patients may be used as a diagnostic tool,
especially when a concurrent analysis is performed for several
salivary markers. Furthermore, this diagnostic tool is of special
importance for patient monitoring, as it is often very difficult to
distinguish clinically between a post operative and/or irradiated
scarred oral mucosa and a recurring cancer lesion. Accordingly,
such an analysis might turn into a valuable diagnostic tool and it
might save many unnecessary biopsies and hospital/out patient
clinic visits. Carbonylation (indication of oxidative damage to
proteins) has attracted a great deal of attention in cancer research
because of its irreversible and unrepairable nature, becoming
Table 1 Statistical analysis of the eight analysed salivary biomarkers
Parameter
% Of change
(out of control) P
Sensitivity
(%)
Specificity
(%)
MMP-9 39 0.014 100 79
Carbonyls 246 0.012 90 80
OGG1  16 0.007 77 75
phospho-Src  24 0.010 77 75
Ki67 127 0.015 58 67
Maspin  29 0.001 100 100
LDH 86 0.002 79 42
CycD1 87 o0.00001 100 100
All were found to be highly significantly altered in the saliva of oral cancer patients as
compared with controls. The following were calculated: percentage of change in the
mean levels of each parameter, statistical significance of the change (represented by P),
sensitivity and specificity values for each biomarker. MMP-9¼metalloproteinase-9;
OGG1¼8-oxoguanine DNA glycosylase; phospho-Src¼phosphorylated-Src;
Maspin¼mammary serine protease inhibitor; LDH¼lactate dehydrogenase;
CycD1¼Cyclin D1.
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Figure 1 Mean activity of salivary LDH (m/l) in healthy controls (Control,
n¼19) and oral cancer patients (Cancer, n¼19), (** P¼0.002).
Table 2 List of biomarkers that were found to be significantly correlated
(r – Pearson correlation coefficient; ro 0.4 or 40.4 – significant
correlation)
Parameters compared r
MMP9–CycD1 0.67
MMP9–carbonyls 0.57
MMP9–Ki67 0.48
Carbonyls–OGG1  0.57
Carbonyls–Ki67 0.72
Carbonyls–Maspin  0.75
Carbonyls–CycD1 0.79
Carbonyls–LDH 0.56
OGG1–Src 0.55
OGG1–Maspin 0.62
OGG1–CycD1  0.54
OGG1–LDH 0.42
Ki67–CycD1 0.54
Maspin–CycD1  0.89
MMP-9¼metalloproteinase-9; OGG1¼8-oxoguanine DNA glycosylase; phospho-
Src¼phosphorylated-Src; Maspin¼mammary serine protease inhibitor; LDH¼
lactate dehydrogenase; CycD1¼Cyclin D1.
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currently reported substantial increase in salivary carbonyls (by
246%) in the OSCC patients is of no surprise, pointing at the
significant free radicals attack to which the epithelial cells
have been exposed. Similarly, it was recently reported that in
malignant tissues (in transitional meningioma and in glioblastoma
multiforme) the degree of oxidative DNA damage (8OHdG) is
increased whereas the total anti-oxidant capacity is decreased
(Hanimoglu et al, 2007; Tuzgen et al, 2007) Indeed, efficient DNA
repair mechanisms comprise a critical component in the protec-
tion against cancer and among these the 8-oxoguanine DNA
glycosylase (OGG1) enzyme is crucial for repairing the oxidative
DNA lesion 8OHdG that is highly mutagenic and carcinogenic.
Most importantly is that reduced activity of OGG1 is considered
an established risk factor for various cancers such as lung and
head and neck cancer (Paz-Elizur et al, 2006, 2008). Hence, the
reduction observed in salivary OGG1 in the OSCC patients
is expected. In a similar manner, the reduction we found for
Maspin is expected. This as Maspin is a tumour supressor protein
that was shown to suppress tumour growth and progression,
angiogenesis, invasion and metastasis in various malignancies
including head and neck cancer (Cho et al, 2007; Iezzi et al, 2007;
Marioni et al, 2008). Accordingly, its reduction is expected
to promote carcinogenesis. In addition, the reduction we noted
for phospho-Src can be explained. Phospho-Src is the inhibited
form of Src and though the latter is expected to be increased,
the first is expected to be decreased in cancer patients as indeed
we noted. A major function of Src (a cytoplasmic kinase) is to
drive adhesion changes that are associated with transition,
proliferation and metastasis (Avizienyte et al, 2005; Chen et al,
2008). Reversible phosphorylation of Src by oxidants and other
agents turn it into its inhibited form, the phospho-Src. In contrast
to OGG1, Maspin and phospho-Src, which were reduced, we found
an increase in the levels of the salivary CysD1, Ki67, LDH and
MMP-9 in the OSCC patients. CycD1 and Ki67 are cell-cycle
regulators, which have been shown to be correlated with cellular
proliferation and tumour progression, metastasis and poor
prognosis (Liu et al, 2003; Adjei, 2005; Wang et al, 2006) and
accordingly are expected to increase in tumours. LDH was found
to increase in the serum of various malignancies and has been
identified as the main recurrent adverse prognostic factors
(Schneider, 2006; Duffy and Crown, 2008; Culine, 2009). As for
the demonstrated increase in MMP-9, it is worth noting that it was
shown earlier to be elevated in saliva (Shpitzer et al, 2007) and
that strong stromal MMP-9-staining intensity was correlated with
poor tumour differentiation (Kosunen et al, 2007). MMP-9 are
metalloproteases that have been shown to participate in cancer
pathogenesis as they degrade type IV collagen, a major component
of basement membrane, as well as other types of collagens (V, VII
and X), elastin and fibronectin. They are highly expressed in
stromal cells surrounding the invading front of metastasising
tumours and their levels are elevated in tumour endothelium and
in urine of cancer patients (Pories et al, 2008; Smith et al, 2008;
Chen et al, 2009). Moreover, MMP-9 polymorphism was shown to
have a strong association with increased risk for developing
OSCC whereas constitutive expression and secretion of
MMP-9 in invasive OSCC cell lines were shown as well (Vairaktaris
et al, 2008).
In summary, the highly significant changes showed for all eight
biomarkers analysed in OSCC patients are encouraging in light of
the many advantages of saliva measurement. It would be highly
desirable and beneficial if salivary tumour marker analysis could
be performed on a routine basis as salivary harvesting is non-
invasive, being an effective alternative to serum testing, and the
possibility of developing self, home testing kits for such markers
further facilitates it as a diagnostic aid. That is especially important
for people who live far from treatment centres and especially for
those at high risk for developing oral cancer (such as patients with
previous OSCC or with pre-malignant lesions). Furthermore, this
study sheds further light on the role of the analysed tumour-
related proteins (markers) in the OSCC pathogenetic network and
also points at a unique opportunity that we may have to intervene
with local therapeutic agents that can be easily applied to the oral
mucosa.
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